Louis Valiquette

Dr. Louis Valiquette

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CCClaire Nour Abou Chakra
Claire Nour Abou Chakra
JPJacques Pepin
Jacques Pepin
SSStephanie Sirard
Stephanie Sirard
LVLouis Valiquette
Louis Valiquette
Clostridium difficile infection (CDI) can lead to complications, recurrence, and death. Numerous studies have assessed risk factors for these unfavourable outcomes, but systematic reviews or meta-analyses published so far were limited in scope or in quality. A systematic review was completed according to PRISMA guidelines. An electronic search in five databases was performed. Studies published until October 2013 were included if risk factors for at least one CDI outcome were assessed with multivariate analyses. 68 studies were included: 24 assessed risk factors for recurrence, 18 for complicated CDI, 8 for treatment failure, and 30 for mortality. Most studies accounted for mortality in the definition of complicated CDI. Important variables were inconsistently reported, such as previous episodes and use of antibiotics. Substantial heterogeneity and methodological limitations were noted, mainly in the sample size, the definition of the outcomes and periods of follow-up, precluding a meta-analysis. Older age, use of antibiotics after diagnosis, use of proton pump inhibitors, and strain type were the most frequent risk factors for recurrence. Older age, leucocytosis, renal failure and co-morbidities were frequent risk factors for complicated CDI. When considered alone, mortality was associated with age, co-morbidities, hypo-albuminemia, leucocytosis, acute renal failure, and infection with ribotype 027. Laboratory parameters currently used in European and American guidelines to define patients at risk of a complicated CDI are adequate. Strategies for the management of CDI should be tailored according to the age of the patient, biological markers of severity, and underlying co-morbidities.

1 September 2007 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
LVLouis Valiquette
Louis Valiquette
BCBenoit Cossette
Benoit Cossette
MGMarie-Pierre Garant
Marie-Pierre Garant
HDHassan Diab
Hassan Diab
JPJacques Pépin
Jacques Pépin
A series of measures were implemented, in a secondary/tertiary-care hospital in Quebec, to control an epidemic of nosocomial Clostridium difficile-as

15 June 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ACAlex Carignan
Alex Carignan
CACatherine Allard
Catherine Allard
JPJacques Pépin
Jacques Pépin
BCBenoit Cossette
Benoit Cossette
VNVincent Nault
Vincent Nault
LVLouis Valiquette
Louis Valiquette
Background. Perioperative antibacterial prophylaxis (PAP) is an important component of surgical site infection prevention but may be associated with adverse effects, such as Clostridium difficile infection (CDI). Since the emergence of a hypervirulent strain of C. difficile, the risk of development of CDI after PAP has not been evaluated. The purpose of this study was to determine the risk of PAP-induced CDI after selected surgical procedures and to compare such risk before with such risk after the emergence of the hypervirulent strain of C. difficile.

28 June 2018 in BMC Public Health
Verified
Journal Article
Open access
PDF file
AGArnaud Gagneur
Arnaud Gagneur
TLThomas Lemaître
Thomas Lemaître
VGVirginie Gosselin
Virginie Gosselin
AFAnne Farrands
Anne Farrands
NCNathalie Carrier
Nathalie Carrier
PWPhilippe De Wals
Philippe De Wals
Due to the increasing number of vaccine-hesitant parents, new effective immunization promotion strategies need to be developed to improve the vaccine coverage (VC) of infants. This study aimed to assess the impact of an educational strategy of vaccination promotion based on motivational interviewing (MI) techniques targeting parents and delivered at the maternity ward, for the VC of infants at 3, 5, and 7 months of age. An individual educational information session, administered using MI techniques, regarding immunization of infants aged 2, 4, and 6 months was (experimental group) or was not (control group) proposed to parents during the postpartum stay at the maternity ward. Immunization data were obtained through the Eastern Townships Public Health registry for infants at 3, 5, and 7 months of age. Absolute VC increases at 3, 5, and 7 months in the experimental group were calculated and the relative risks with the respective 95% confidence intervals were computed using univariate logistic regression with the generalized estimating equations (GEE) procedure. Multivariate regression using GEE was used to adjust for confounding variables. In the experimental and control groups, 1140 and 1249 newborns were included, respectively. A significant increase in VC of 3.2, 4.9, and 7.3% was observed at 3, 5, and 7 months of age (P < 0.05), respectively. The adjusted relative risk of the intervention’s impact on vaccination status at 7 months of age was 1.08 (95% confidence interval: 1.03–1.14) (P = 0.002). An educational strategy using MI techniques delivered at the maternity ward may be effective in increasing VC of infants at ages 3, 5, and 7 months. MI could be an effective tool to overcome vaccine hesitancy.

30 December 2010 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MGMilagros Gonzales
Milagros Gonzales
JPJacques Pepin
Jacques Pepin
EFEric Frost
Eric Frost
JCJulie C Carrier
Julie C Carrier
SSStephanie Sirard
Stephanie Sirard
LVLouis Valiquette
Louis Valiquette
Background: Oral vancomycin (125 mg qid) is recommended as treatment of severe Clostridium difficile infection (CDI). Higher doses (250 or 500 mg qid) are sometimes recommended for patients with very severe CDI, without supporting clinical evidence. We wished to determine to what extent faecal levels of vancomycin vary according to diarrhoea severity and dosage, and whether it is rational to administer high-dose vancomycin to selected patients. Methods: We recruited hospitalized adults suspected to have CDI for whom oral vancomycin (125, 250 or 500 mg qid) had been initiated. Faeces were collected up to 3 times/day and levels were measured with the AxSYM fluorescence polarization immunoassay. Results: Fifteen patients (9 with confirmed CDI) were treated with oral vancomycin. Patients with ≥4 stools daily presented lower faecal vancomycin levels than those with a lower frequency. Higher doses of oral vancomycin (250 mg or 500 mg qid) led to consistently higher faecal levels (> 2000 mg/L), which were 3 orders of magnitude higher than the MIC90 of vancomycin against C. difficile. One patient receiving 125 mg qid had levels below 50 mg/L during the first day of treatment. Conclusions: Faecal levels of vancomycin are proportional to the dosage administered and, even in patients with increased stool frequency, much higher than the MIC90. Patients given the standard 125 mg qid dosage might have low faecal levels during the first day of treatment. A loading dose of 250 mg or 500 mg qid during the first 24-48 hours followed by the standard dosage should be evaluated in larger studies, since it might be less disruptive to the colonic flora and save unnecessary costs.

17 November 2015 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CSCaroline Sheitoyan-Pesant
Caroline Sheitoyan-Pesant
CCClaire Nour Abou Chakra
Claire Nour Abou Chakra
JPJacques Pépin
Jacques Pépin
AMAnaïs Marcil-Héguy
Anaïs Marcil-Héguy
VNVincent Nault
Vincent Nault
LVLouis Valiquette
Louis Valiquette
Background. Clostridium difficile infection (CDI) is associated with a high risk of recurrence (rCDI). Few studies have focused on multiple recurrences. To evaluate the potential of novel treatments targeting recurrence, we assessed the burden and severity of rCDI. Methods. This was a retrospective cohort of adults diagnosed with CDI in a hospital in Sherbrooke, Canada (1998–2013). An rCDI episode was defined by the reappearance of diarrhea leading to a treatment, with or without a positive toxin assay, within 14–60 days after the previous episode. Results. We included 1527 patients. The probability of developing a first rCDI was 25% (354/1418); a second, 38% (128/334); a third, 29% (35/121); and a fourth or more, 27% (9/33). Two or more rCDIs were observed in 9% (128/1389) of patients. The risk of a first recurrence fluctuated over time, but there was no such variation for second or further recurrences. The proportion of severe cases decreased (47% for initial episodes, 31% for first recurrences, 25% for second, 17% for third), as did the risk of complicated CDI (5.8% to 2.8%). The severity and risk of complications of first recurrences decreased over time, while oral vancomycin was used more systemically. A hospital admission was needed for 34% (148/434) of recurrences. Conclusions. This study documented the clinical and healthcare burden of rCDI: 34% of patients with rCDI needed admission, 28% developed severe CDI, and 4% developed a complication. Secular changes in the severity of recurrences could reflect variations in the predominant strain, or better management.